Clinical Trial Update: Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rifaximin in combination with classic triple therapy to eradicate Helicobacter pylori. Results for the study were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Helicobacter Pylori Infection

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Conditions: Bacterial Infection Due to Helicobacter Pylori (H. Pylori) | Phase 3 | Status: COMPLETED | Results posted: 2018-02-19